Potential applications of PET/MR imaging in cardiology

Journal of Nuclear Medicine

Volumn 55, Issue 6 SUPPL. 2, 2014, Pages

  Ratib, Osman ^a   Nkoulou, René ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cardiac PET; Hybrid PET MRI; Nuclear cardiology

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM; SODIUM FLUORIDE F 18;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DIAGNOSTIC ACCURACY; HEART INFARCTION; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HUMAN; MYOCARDIAL PERFUSION IMAGING; PRIORITY JOURNAL; REPRODUCIBILITY; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION;

EID: 84903135090     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.129262     Document Type: Article

References (50)

1. Flotats A, Knuuti J, Gutberlet M, et al. Hybrid cardiac imaging: SPECT/CT and PET/CT - a joint position statement by the European Association of Nuclear Medicine (EANM), the European Society of Cardiac Radiology (ESCR) and the European Council of Nuclear Cardiology (ECNC). Eur J Nucl Med Mol Imaging. 2011;38:201-212.
2. Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008;29:480-489. (Pubitemid 351264187)
3. Balyasnikova S, Lofgren J, de Nijs R, Zamogilnaya Y, Hojgaard L, Fischer BM. PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. Am J Nucl Med Mol Imaging. 2012;2:458-474.
4. Torigian DA, Zaidi H, Kwee TC, et al. PET/MR imaging: technical aspects and potential clinical applications. Radiology. 2013;267:26-44.
5. Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med. 2013;54:402-415.
6. Ratib O, Nkoulou R, Schwaiger M. PET/MRI: a new era in multimodality molecular imaging. Clin Transl Imaging. 2013;1:10.
7. Levitt K, Guo H, Wijeysundera HC, et al. Predictors of normal coronary arteries at coronary angiography. Am Heart J. 2013;166:694-700.
8. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516. (Pubitemid 46588415)
9. Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56:177-184.
10. De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001.
11. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2007;50:1343-1353.
12. de Jong MC, Genders TS, van Geuns RJ, Moelker A, Hunink MG. Diagnostic performance of stress myocardial perfusion imaging for coronary artery disease: a systematic review and meta-analysis. Eur Radiol. 2012;22:1881-1895.
13. Fiechter M, Stehli J, Fuchs TA, Dougoud S, Gaemperli O, Kaufmann PA. Impact of cardiac magnetic resonance imaging on human lymphocyte DNA integrity. Eur Heart J. 2013;34:2340-2345.
14. Nael K, Fenchel M, Saleh R, Finn JP. Cardiac MR imaging: new advances and role of 3T. Magn Reson Imaging Clin N Am. 2007;15:291-300. (Pubitemid 47430008)
15. Schwitter J, Wacker CM, Wilke N, et al. MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease - a comparative multicentre, multivendor trial. Eur Heart J. 2013;34:775-781.
16. Ibrahim T, Nekolla SG, Schreiber K, et al. Assessment of coronary flow reserve: comparison between contrast-enhanced magnetic resonance imaging and positron emission tomography. J Am Coll Cardiol. 2002;39:864-870. (Pubitemid 34185336)
17. Sdringola S, Johnson NP, Kirkeeide RL, Cid E, Gould KL. Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers. JACC Cardiovasc Imaging. 2011;4:402-412.
18. 13N-ammonia myocardial perfusion PET: added value of myocardial flow reserve. J Nucl Med. 2012;53:1230-1234.
19. Schindler TH, Nitzsche EU, Schelbert HR, et al. Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. J Am Coll Cardiol. 2005;45:1505-1512. (Pubitemid 40615626)
20. Sherif HM, Nekolla SG, Saraste A, et al. Simplified quantification of myocardial flow reserve with flurpiridaz F 18: validation with microspheres in a pig model. J Nucl Med. 2011;52:617-624.
21. 15O-labeled water and positron emission tomography. J Nucl Cardiol. 2011;18:650-656.
22. Zaidi H, Nkoulou R, Bond S, et al. Computed tomography calcium score scan for attenuation correction of N-13 ammonia cardiac positron emission tomography: effect of respiratory phase and registration method. Int J Cardiovasc Imaging. 2013;29:1351-1360.
23. Rees G, Bristow JD, Kremkau EL, et al. Influence of aortocoronary bypass surgery on left ventricular performance. N Engl J Med. 1971;284:1116-1120.
24. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375-410. (Pubitemid 46881171)
25. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002-2012. (Pubitemid 350054917)
26. Cleland JG, Calvert M, Freemantle N, et al. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail. 2011;13:227-233.
27. Schinkel AF, Poldermans D, Elhendy A, Bax JJ. Assessment of myocardial viability in patients with heart failure. J Nucl Med. 2007;48:1135-1146. (Pubitemid 47052654)
28. 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results. Nucl Med Commun. 1998;19:867-874.
29. 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2010;51:567-574.
30. Patterson RE, Sigman SR, O'Donnell RE, Eisner RL. Viability assessment with MRI is superior to FDG-PET for viability: Con. J Nucl Cardiol. 2010;17:298-309.
31. Kato S, Kitagawa K, Ishida N, et al. Assessment of coronary artery disease using magnetic resonance coronary angiography: a national multicenter trial. J Am Coll Cardiol. 2010;56:983-991.
32. Eisentopf J, Achenbach S, Ulzheimer S, et al. Low-dose dual-source CT angiography with iterative reconstruction for coronary artery stent evaluation. JACC Cardiovasc Imaging. 2013;6:458-465.
33. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103:253-258. (Pubitemid 23027268)
34. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122:1895-1901. (Pubitemid 36051121)
35. Takeda N, Yokoyama I, Hiroi Y, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation. 2002;105:1144-1145. (Pubitemid 34212627)
36. 18F-FDG PET. J Nucl Med. 2003;44:1030-1036.
37. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329-336.
38. Nery PB, McArdle BA, Redpath CJ, et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2014;37:364-374.
39. 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933-941.
40. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-193. (Pubitemid 40139730)
41. Falk RH, Dorbala S. Pursuing an underdiagnosed disease: a simple imaging test for increasing suspicion of cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2011;38:467-469.
42. 11C-PIB and PET. J Nucl Med. 2013;54:213-220.
43. Chen W, Dilsizian V. Molecular imaging of amyloidosis: will the heart be the next target after the brain? Curr Cardiol Rep. 2012;14:226-233.
44. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56-62.
45. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-235.
46. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13-C18.
47. 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging. 2009;2:331-338.
48. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39(suppl 1):S126-S138.
49. 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59:1539-1548.
50. 18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. J Nucl Cardiol. 2012;19:1211-1225.